US drug companies are increasingly licensing experimental medicines invented by Chinese firms. The recent deals could be ...

The VeriTac-2 trial assessed vepdegestrant (ARV-471) as a monotherapy compared to fulvestrant in patients with ER+/HER2* ...

Arvinas and Pfizer have filed for U.S. Food and Drug Administration approval of their proposed breast-cancer drug vepdegestrant in certain patients with estrogen-receptor mutations.

Investors looking for sources of passive income to fuel their retirement dreams face a dilemma. Lately, Pfizer (NYSE: PFE) ...

Jefferies reaffirms its Buy rating on Pfizer and sticks to a $33 target, calling the stock undervalued at $23.35. Their ...

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

Last month, the Centers for Medicare & Medicaid Services began meeting with patients who use the 15 drugs it selected for the second round of Medicare price "negotiations" — including ...

We recently published a list of Jim Cramer Recently Discussed These 15 Stocks. In this article, we are going to take a look ...

Moderna was recently told that the Health and Human Services Department (HHS) had withdrawn a $766million grant awarded by ...

The oncology giant will pay $1.5 billion to co-develop a BioNTech drug that targets the proteins PD-L1 and VEGF, following ...

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Pfizer ...